Protein & Cell >

2018 , Vol. 9 >Issue 1: 135 - 139

DOI: https://doi.org/10.1007/s13238-017-0412-8

LETTER

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

  • Shuguang Tan 1 ,
  • Kefang Liu 2,3 ,
  • Yan Chai 1 ,
  • Catherine W.-H. Zhang 4 ,
  • Shan Gao 5 ,
  • George F. Gao 1,2,3 ,
  • Jianxun Qi , 1
Expand
  • 1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China
  • 2. National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China
  • 3. College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, China
  • 4. ImmuFuCell Biotechnology Co.Ltd., Beijing 100102, China
  • 5. CAS Key Laboratory of Bio-medical Diagnostic, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou 215163, China

Published date: 01 Mar 2018

Copyright

2017 The Author(s) 2017. This article is an open access publication
Fold

Cite this article

Shuguang Tan , Kefang Liu , Yan Chai , Catherine W.-H. Zhang , Shan Gao , George F. Gao , Jianxun Qi . Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab[J]. Protein & Cell, 2018 , 9(1) : 135 -139 . DOI: 10.1007/s13238-017-0412-8

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, Narwal R, Steele K, Gu Y, Karakunnel JJ (2016) Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17:299–308

2
Kim JM, Chen DS (2016) Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27:1492–1504

3
Larkin J, Hodi FS, Wolchok JD (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373:1270–1271

4
Lee JY, Lee HT, Shin W, Chae J, Choi J, Kim SH, Lim H, Won Heo T, Park KY, Lee YJ (2016) Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. Nat Commun 7:13354

5
Liu K, Tan S, Chai Y, Chen D, Song H, Zhang CW, Shi Y, Liu J, Tan W, Lyu J (2017) Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res 27:151–153

6
Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC (2015)Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA 112:E6506–E6514

7
Na Z, Yeo SP, Bharath SR, Bowler MW, Balikci E, Wang CI, Song H (2017) Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res 27:147–150

8
Palucka AK, Coussens LM (2016) The Basis of Oncoimmunology. Cell 164:1233–1247

9
Tan S, Chen D, Liu K, He M, Song H, Shi Y, Liu J, Zhang CW, Qi J, Yan J (2016a) Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. Protein Cell 7:866–877

10
Tan S, Zhang CW, Gao GF (2016b) Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduct Target Ther. doi:10.1038/sigtrans.2016.1029

11
Tan S, Zhang H, Chai Y, Song H, Tong Z, Wang Q, Qi J, Wong G, Zhu X, Liu WJ (2017) An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun 8:14369

12
Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Domling A, Dubin G, Holak TA (2015) Structure of the Complex of Human ProgrammedDeath1, PD-1,andItsLigandPD-L1. Structure 23:2341–2348

13
Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Domling A, Dubin G, Holak TA (2016) Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7:30323–30335

14
Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T (2017) Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov 3:17004

Options
Outlines

/

〈 〉